MCID: PRP036
MIFTS: 53

Peripheral T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 12 74 52 15 37 71
Peripheral T Cell Lymphoma 36
Lymphoma T-Cell Peripheral 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050749
KEGG 36 H01892
ICD10 32 C84.4
UMLS 71 C0079774

Summaries for Peripheral T-Cell Lymphoma

KEGG : 36 Peripheral T cell lymphomas (PTCLs) are a group of rare lymphomas originating from mature (i.e., post-thymic or "peripheral") T lymphocytes and NK cells. With regard to the current WHO classification, leukemic, cutaneous, nodal, and extranodal PTCL are distinguished. The most common subtypes worldwide are the nodal T cell lymphomas. In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. Novel approaches are gradually clarifying the molecular pathogenesis of PTCLs. ALK gene translocation and dual specificity phosphatase 22 (DUSP22) gene translocation are seen in ALK-positive ALCL and ALK-negative ALCL, respectively. Recently, gene mutations in epigenetic regulators, including Ten-Eleven Translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), and isocitrate dehydrogenase 1 /2 (IDH1/2), are discovered in hematologic malignancies. The mutation frequencies were especially high in AITL and PTCL-NOS.

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as peripheral t cell lymphoma, is related to angioimmunoblastic t-cell lymphoma and anaplastic large cell lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TNFRSF8 (TNF Receptor Superfamily Member 8), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Epirubicin and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and nk cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.

Wikipedia : 74 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 440)
# Related Disease Score Top Affiliating Genes
1 angioimmunoblastic t-cell lymphoma 33.4 TNFRSF8 TIA1 SYK MME GZMB CXCL13
2 anaplastic large cell lymphoma 32.3 TNFRSF8 TIA1 GZMB CXCR3 CCR4 ALK
3 lymphoma 32.1 TP53 TNFRSF8 TIA1 TCL1A MS4A1 MME
4 adult t-cell leukemia 32.0 TP53 TNFRSF8 IL2 CCR4
5 t-cell lymphoma, subcutaneous panniculitis-like 31.9 TNFRSF8 TIA1 GZMB ALK
6 alk-positive anaplastic large cell lymphoma 31.9 TNFRSF8 ALK
7 alk-negative anaplastic large cell lymphoma 31.8 CXCR3 CCR4 ALK
8 hepatosplenic t-cell lymphoma 31.8 TIA1 GZMB
9 t-cell leukemia 31.8 TP53 TCL1A IL2RB IL2 CCR4
10 lethal midline granuloma 31.7 TNFRSF8 TIA1 NCAM1
11 cutaneous t cell lymphoma 31.6 TNFRSF8 TIA1 IL2RB IL2 GZMB CXCR3
12 composite lymphoma 31.6 TNFRSF8 TIA1 MME GZMB BCL6
13 lymphoma, hodgkin, classic 31.6 TNFRSF8 TIA1 MS4A1 IL2 GZMB CCR4
14 panniculitis 31.6 TNFRSF8 TIA1 NCAM1 GZMB CD8A
15 lymphocytic leukemia 31.5 TP53 MS4A1 MME IL2 ETV6
16 lymphoblastic lymphoma 31.5 TP53 TNFRSF8 MME CD8A BCL6
17 diffuse large b-cell lymphoma 31.4 TP53 TNFRSF8 TCL1A SYK NCAM1 MME
18 marginal zone b-cell lymphoma 31.4 TNFRSF8 MME BCL6
19 follicular lymphoma 31.4 SYK MS4A1 MME BCL6
20 b-cell lymphoma 31.4 TP53 TNFRSF8 TIA1 TCL1A SYK MS4A1
21 primary cutaneous t-cell lymphoma 31.4 TNFRSF8 MS4A1
22 t-cell adult acute lymphocytic leukemia 31.4 TP53 TNFRSF8 TIA1 IL2 CD8A ALK
23 prolymphocytic leukemia 31.4 TP53 TCL1A MS4A1
24 mycosis fungoides 31.3 TNFRSF8 TIA1 NCAM1 IL2RB IL2 GZMB
25 lymphomatoid granulomatosis 31.3 TIA1 GZMB
26 nodular lymphocyte predominant hodgkin lymphoma 31.3 TNFRSF8 BCL6
27 primary cutaneous anaplastic large cell lymphoma 31.3 TIA1 GZMB ALK
28 cll/sll 31.3 TP53 MME BCL6
29 dermatitis 31.2 IL2 GZMB CXCR3 CCR4
30 lymphomatoid papulosis 31.2 TNFRSF8 TIA1 GZMB ALK
31 central nervous system lymphoma 31.2 TP53 IL2 CXCL13 BCL6
32 lung lymphoma 31.1 TNFRSF8 MME BCL6
33 acquired immunodeficiency syndrome 31.0 TP53 IL2RB IL2 BCL6
34 breast lymphoma 31.0 TNFRSF8 MME BCL6 ALK
35 mantle cell lymphoma 31.0 TP53 TCL1A SYK MS4A1 MME BCL6
36 celiac disease 1 31.0 NCAM1 IL2RB IL2 GZMB CD8A
37 pfeiffer syndrome 31.0 TNFRSF8 IL2RB IL2 FGFR3 CD8A
38 reticulosarcoma 30.9 TNFRSF8 TIA1 GZMB BCL6 ALK
39 marek disease 30.9 TP53 TNFRSF8
40 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.9 TNFRSF8 BCL6
41 plasma cell leukemia 30.9 NCAM1 FGFR3
42 fasciitis 30.9 TP53 SYK IL2 ETV6
43 gastrointestinal lymphoma 30.9 TNFRSF8 MME BCL6
44 sezary's disease 30.8 TNFRSF8 NCAM1 IL2RB IL2 CD8A CCR4
45 colon lymphoma 30.8 MME BCL6
46 aggressive nk-cell leukemia 30.8 TIA1 NCAM1 GZMB
47 sarcoidosis 1 30.7 IL2RB IL2 CXCR3 CD8A
48 parapsoriasis 30.7 TNFRSF8 CD8A
49 seminoma 30.7 TP53 TNFRSF8 TCL1A NME1 FGFR3
50 tropical spastic paraparesis 30.7 IL2RB IL2 CXCR3

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 BCL6 CCR4 CD8A CXCL13 CXCR3 ETV6
2 immune system MP:0005387 10.24 BCL6 CCR4 CD8A CXCL13 CXCR3 ETV6
3 cellular MP:0005384 10.2 BCL6 CD8A CXCL13 CXCR3 ETV6 FGFR3
4 endocrine/exocrine gland MP:0005379 10.13 ALK BCL6 CD8A ETV6 IL2 IL2RB
5 integument MP:0010771 9.97 ALK BCL6 CD8A ETV6 FGFR3 IL2RB
6 mortality/aging MP:0010768 9.97 ALK BCL6 CD8A CXCR3 ETV6 FGFR3
7 liver/biliary system MP:0005370 9.8 BCL6 IL2 IL2RB MME NME1 SYK
8 neoplasm MP:0002006 9.5 ALK CXCR3 ETV6 FGFR3 IL2 NME1
9 respiratory system MP:0005388 9.23 ALK BCL6 CCR4 CXCR3 FGFR3 IL2

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
3
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
4
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
5
Dacarbazine Approved, Investigational Phase 4 4342-03-4 5351166
6
Busulfan Approved, Investigational Phase 4 55-98-1 2478
7
Infliximab Approved Phase 4 170277-31-3
8
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
9
Apatinib Phase 4 811803-05-1
10 Antibodies, Blocking Phase 4
11 Gastrointestinal Agents Phase 4
12
asparaginase Phase 4
13 Thymoglobulin Phase 4
14
Vinblastine Approved Phase 3 865-21-4 13342 241903
15
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
16
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
17
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
18
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
19
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
20
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
21
Cobalamin Experimental Phase 3 13408-78-1 6857388
22 Hematinics Phase 3
23 Hormone Antagonists Phase 3
24 Anti-Inflammatory Agents Phase 3
25 Antineoplastic Agents, Hormonal Phase 3
26 glucocorticoids Phase 3
27 Hormones Phase 3
28 Vitamins Phase 3
29 Vitamin B 12 Phase 3
30 Vitamin B12 Phase 3
31 10-deazaaminopterin Phase 3
32
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
33
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
34
Gemcitabine Approved Phase 2 95058-81-4 60750
35
leucovorin Approved Phase 2 58-05-9 6006 143
36
Mesna Approved, Investigational Phase 2 3375-50-6 598
37
Mogamulizumab Approved, Investigational Phase 2 1159266-37-1
38
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
39
Adenosine Approved, Investigational Phase 2 58-61-7 60961
40
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
41
Bevacizumab Approved, Investigational Phase 2 216974-75-3
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
44
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 23925 27284
45
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
46
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
47
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2
48
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
50
Atezolizumab Approved, Investigational Phase 2 1380723-44-3

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
2 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03631862 Phase 4 Apatinib;CHOP Regimen
3 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Peripheral T-cell Lymphoma Recruiting NCT04040491 Phase 4 PD-1 blocking antibody, chidamide, lenalidomide and etoposide
4 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
5 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
6 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
7 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
8 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
9 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
10 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
11 Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
12 A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
13 A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT03349333 Phase 3 pralatrexate
14 A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas Completed NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
15 Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03952572 Phase 3 Cyclophosphamide;pegylated liposomal doxorubicin;Vincristine;Prednisone;Doxorubicin
16 Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
17 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
18 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
19 Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Not yet recruiting NCT03553537 Phase 3 Decitabine;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
20 A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy Terminated NCT01420679 Phase 3 Pralatrexate Injection
21 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
22 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
23 A Multi-center, Prospective, Single-arm, Open Label Phase II Study of Chidamide Combined With Chemotherapy in the Treatment of Peripheral T Cell Lymphoma Unknown status NCT02753543 Phase 2 Chidamide
24 A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma. Unknown status NCT00211185 Phase 2 ONTAK (denileukin diftitox, DAB389 IL-2)
25 Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma: A Phase II Clinical Trial Unknown status NCT02856997 Phase 2 Chidamide with ICE regimen
26 Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma, a Single-Center, Nonrandomized Phase II Clinical Trial Unknown status NCT02944812 Phase 2 Chidamide
27 A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Unknown status NCT00299351 Phase 2 Depsipeptide
28 Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
29 Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial Unknown status NCT00632827 Phase 2 REGIMEN;REGIMEN B
30 The Efficacy and Toxicity of GDP Chemotherapy in Patients With Peripheral T-cell Lymphoma: An Open-label, Single-arm, Phase II Clinical Trial Unknown status NCT02404571 Phase 2 GDP chemotherapy
31 An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Unknown status NCT02464228 Phase 2 Tipifarnib
32 The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study. Unknown status NCT02520219 Phase 2 GDP
33 Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) Unknown status NCT03105596 Phase 2 Chidamide plus DICE Regimen
34 Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65 Unknown status NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
35 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
36 Pilot Study of GC. (Gemcitabine-Rituximab-Oxaliplatin Combination) Given Every 14 Days With Maintenance Lenalidomide for the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Unknown status NCT01307592 Phase 2 gemcitabine hydrochloride;lenalidomide;oxaliplatin
37 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
38 Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL Unknown status NCT00840385 Phase 2 FAD
39 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Unknown status NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
40 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
41 Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation Completed NCT01806337 Phase 2 Alemtuzumab
42 Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients. Completed NCT01822886 Phase 2 Romidepsin + Gemcitabine
43 A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Completed NCT02676778 Phase 2 E7777
44 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT02013362 Phase 1, Phase 2 Pralatrexate injection
45 Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients Completed NCT01776411 Phase 1, Phase 2 forodesine hydrochloride
46 A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT00865969 Phase 2 PXD101
47 A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT00364923 Phase 2 Pralatrexate Injection
48 A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma Completed NCT01456039 Phase 1, Phase 2 Romidepsin
49 Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001 Completed NCT01226472 Phase 2
50 A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma Completed NCT00136565 Phase 2 Velcade;Doxorubicin;Prednisone;Cyclophosphamide;Vindesine;Bleomycin

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

40
T Cells, B Cells, Nk Cells, Bone, Thymus, Bone Marrow, Liver

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 2365)
# Title Authors PMID Year
1
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. 54 61
20217288 2010
2
Primary cutaneous follicular variant of peripheral T-cell lymphoma NOS. A report of two cases. 54 61
20459562 2010
3
Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. 54 61
19710685 2010
4
Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. 54 61
19377442 2009
5
[Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis]. 54 61
19575875 2009
6
[Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. 54 61
19575892 2009
7
Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. 54 61
19365529 2009
8
Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation. 54 61
18842429 2009
9
[Peripheral T-cell lymphoma, NOS arising in Warthin tumor: report of a case]. 54 61
19031731 2008
10
Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. 54 61
18425045 2008
11
Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. 54 61
17582237 2007
12
Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. 54 61
17431414 2007
13
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 54 61
17430665 2007
14
[Expression and clinical significance of Mcl-1 in T-cell non-Hodgkin's lymphoma]. 54 61
17430669 2007
15
[Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma]. 54 61
17166378 2006
16
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 54 61
16680156 2006
17
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. 54 61
16341044 2006
18
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. 54 61
16091734 2005
19
Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. 54 61
16160469 2005
20
Peripheral T-cell lymphoma not otherwise specified vs. Hodgkin's lymphoma on fine needle aspiration cytology. 54 61
16124164 2005
21
Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. 54 61
15925824 2005
22
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. 54 61
15514005 2005
23
Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). 54 61
15965283 2005
24
Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. 54 61
15531460 2004
25
CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. 54 61
15328188 2004
26
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. 54 61
15105810 2004
27
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 54 61
15133473 2004
28
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. 54 61
14616965 2003
29
Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. 54 61
12707037 2003
30
CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. 54 61
11979374 2002
31
T-cell receptor Vbeta repertoire in nodal non-anaplastic peripheral T-cell lymphomas. 54 61
12166895 2002
32
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. 54 61
11731410 2001
33
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. 54 61
11222361 2001
34
Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. 54 61
11235901 2001
35
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 54 61
10786666 2000
36
Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. 54 61
10414505 1999
37
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. 54 61
9736036 1998
38
Amplification of the TCL1 flanking region at 14q32.1 with no TCL1 gene transcription in a patient with peripheral T cell lymphoma. 54 61
9639427 1998
39
Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis. 54 61
8655683 1996
40
High-grade pleomorphic T cell lymphoma with restricted involvement of skin and bone marrow. 54 61
8513200 1993
41
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. 54 61
1373974 1992
42
[Midline malignant reticulosis: a histopathological, ultrastructural and immunohistochemical study of 11 cases]. 54 61
1813158 1991
43
Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. 54 61
1652981 1991
44
Activated-cytotoxic TCRαβ+CD4+ peripheral T-cell lymphoma with hypodermal localization: Case report of a lymphoproliferative disorder probably evolved from the CD4+ cytotoxic T-cell subpopulation. 61
31595546 2020
45
A retrospective review of cutaneous lymphoma in Botswana. 61
31647120 2020
46
Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review. 61
31482600 2020
47
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. 61
32016790 2020
48
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. 61
31558781 2020
49
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. 61
31028364 2020
50
Peripheral T-Cell Lymphoma Presenting as Pseudoachalasia. 61
31464744 2020

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 TP53 TNFRSF8 IL2RB IL2 FGFR3 CXCR3
2
Show member pathways
13.53 TP53 TNFRSF8 IL2RB IL2 FGFR3 CXCR3
3
Show member pathways
13.21 TP53 TNFRSF8 SYK NCAM1 IL2RB IL2
4
Show member pathways
13.17 TP53 TNFRSF8 SYK IL2RB IL2 FGFR3
5
Show member pathways
13.16 TNFRSF8 IL2RB IL2 FGFR3 CXCR3 CXCL13
6
Show member pathways
12.84 TP53 TCL1A SYK IL2RB IL2 FGFR3
7 12.7 TP53 IL2RB IL2 FGFR3 ALK
8
Show member pathways
12.19 IL2RB IL2 CXCR3 CXCL13 CCR4
9 12.1 TP53 IL2RB GZMB ETV6 BCL6
10 12.07 TNFRSF8 SYK NCAM1 IL2RB IL2 GZMB
11 11.98 SYK IL2RB FGFR3 ALK
12
Show member pathways
11.83 IL2RB IL2 GZMB CD8A
13 11.7 NCAM1 MS4A1 MME IL2RB IL2 CD8A
14 11.52 NCAM1 MS4A1 MME IL2 CD8A
15
Show member pathways
11.49 IL2RB IL2 GZMB CD8A
16 11.39 TNFRSF8 MS4A1 MME BCL6
17
Show member pathways
11.07 SYK IL2RB IL2
18 11 NCAM1 IL2RB IL2 GZMB CXCR3 CD8A

GO Terms for Peripheral T-Cell Lymphoma

Cellular components related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.8 TP53 NME1 MS4A1 IL2 CXCR3 CXCL13
2 cell surface GO:0009986 9.63 NCAM1 MS4A1 MME IL2RB FGFR3 CXCR3
3 integral component of plasma membrane GO:0005887 9.56 MS4A1 MME IL2RB FGFR3 CXCR3 CD8A
4 external side of plasma membrane GO:0009897 9.1 NCAM1 MS4A1 IL2RB CXCR3 CD8A CCR4

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 TP53 TCL1A IL2RB IL2 BCL6
2 regulation of apoptotic process GO:0042981 9.86 TP53 NME1 BCL6 ALK
3 immune response GO:0006955 9.85 IL2 CXCR3 CXCL13 CD8A CCR4
4 MAPK cascade GO:0000165 9.78 NCAM1 IL2RB IL2 FGFR3
5 cell chemotaxis GO:0060326 9.71 CXCR3 CXCL13 CCR4
6 cell surface receptor signaling pathway GO:0007166 9.71 SYK CXCR3 CXCL13 CD8A
7 chemokine-mediated signaling pathway GO:0070098 9.54 CXCR3 CXCL13 CCR4
8 replicative senescence GO:0090399 9.52 TP53 MME
9 positive regulation of regulatory T cell differentiation GO:0045591 9.51 IL2 BCL6
10 positive regulation of histone deacetylation GO:0031065 9.49 TP53 BCL6
11 positive regulation of cytosolic calcium ion concentration GO:0007204 9.46 IL2 CXCR3 CXCL13 CCR4
12 positive regulation of protein oligomerization GO:0032461 9.43 TP53 TCL1A
13 negative regulation of B cell apoptotic process GO:0002903 9.32 IL2 BCL6
14 germinal center formation GO:0002467 9.26 CXCL13 BCL6
15 leukocyte activation involved in immune response GO:0002366 8.96 SYK IL2
16 interleukin-2-mediated signaling pathway GO:0038110 8.8 SYK IL2RB IL2

Molecular functions related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 TP53 TNFRSF8 TIA1 TCL1A SYK NME1
2 identical protein binding GO:0042802 9.5 TP53 TCL1A NME1 FGFR3 CXCR3 BCL6

Sources for Peripheral T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....